GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open framework agreement on drug discounts pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), with the possibility of joining at any time, so-called approval model 2025-07

Original title (German): Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-07

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

July 05, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open framework agreement on drug discounts pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), with the possibility of joining at any time, so-called approval model 2025-07

This is one of 1,390 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedJuly 21, 2025
Procurement stageActive solicitation
Response dueJuly 05, 2027
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV88
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin zeta, ATC B03AX01
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Baumpollen, ATC V01AA05
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Nilotinib (ATC: L01EA03)
Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Timolol und Tafluprost (ATC: S01ED70)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Eisen (parenterale Zubereitungen), ATC B03AC07 f. d. Z. 01.11.25-31.10.27 (zzgl.Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Formoterol, Glycopyrroniumbromid und Budesonid , ATC R03AL11
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient fondaparinux (ATC code: B01AX05).

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.